ClinicalTrials.gov
public full text
Public Domain
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors#1410393
- Efficacy and Safety Evaluation of BZ371B in ARDS Patients#1137501
- RY_SW01 Cell Injection Therapy in Active Lupus Nephritis#845065
- MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients#1259588
- GT719 Injection for Moderate to Severe Refractory Autoimmune Disease#907519
Record · ID 1419456
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive